Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG Glaxo
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravesical
01
Overview
BCG Glaxo is a specific substrain of the Bacillus Calmette-Guérin (BCG) vaccine, derived from a live attenuated strain of *Mycobacterium bovis*. It is classified as an evolutionarily "late" strain due to the loss of the Region of Differentiation 2 (RD2) genomic segment. Historically, it was utilized for the prevention of tuberculosis and as an intravesical immunotherapy for non-muscle invasive bladder cancer (NMIBC), particularly carcinoma in situ. The mechanism involves the stimulation of a local inflammatory and cellular immune response, characterized by the production of cytokines such as interleukin-6 and interleukin-8, which leads to the destruction of tumor cells. However, comparative studies have indicated that the Glaxo strain may be less immunogenic and efficacious than other substrains like Connaught or Russian. Production was eventually transferred to Evans Medical (later Medeva), and the strain is currently largely discontinued in clinical practice.
- Brand names
- BCG Vaccine Glaxo
- Other names
- Glaxo-Evans strainBCG Glaxo-EvansMycobacterium bovis BCG substrain Glaxo
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BCG Glaxo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG Glaxo.